Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial

Cancer Science
Yasuyoshi MoritaMitsuhiro Matsuda

Abstract

Although azacitidine is the first-line drug for higher-risk myelodysplastic syndrome (MDS) patients, its efficacy for lower-risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5-day regimen of azacitidine (AZA-5) for lower-risk MDS. The primary endpoint was hematological improvement (HI) after 4 courses of therapy. A total of 51 patients with lower-risk MDS based on the French-American-British (FAB) classification (44 patients with refractory anemia [RA] and 7 patients with refractory anemia with ringed sideroblasts [RARS]) were enrolled from 6 centers in Japan. The median age was 75 years (range: 51-88). These patients received AZA-5 (75 mg/m2 ; once daily for 5 sequential days). The median number of AZA-5 courses was 8 (range: 1-57), and 45 patients (88.2%) received more than 4 courses. HI and transfusion independency were seen in 24 patients (47.1%) and 11 patients (39.2%), respectively. A total of 11 patients (21.6%) achieved complete remission or marrow remission. WT1 mRNA levels were not significantly correlated with therapy response. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 26 (51.0%) and 11 (21.5%) patients, respectively. Nonhematological g...Continue Reading

References

Jan 22, 2005·Annual Review of Medicine·Wolf-K Hofmann, H Phillip Koeffler
Dec 15, 2007·Leukemia·G Garcia-ManeroH Kantarjian
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger M LyonsC L Beach
Jun 1, 2011·Cancer Science·Toshiki UchidaTomomitsu Hotta
Apr 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla FilìDomenico Russo
Apr 12, 2016·Cancer Biomarkers : Section a of Disease Markers·Sumiko KobayashiFumimaro Takaku
Mar 30, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sophie ParkPierre Fenaux
Aug 22, 2017·Leukemia Research·Je-Hwan LeeUNKNOWN AML MDS Working Party of the Korean Society of Hematology

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
Assay

Software Mentioned

IPSS
R commander
CTCAE
R
EZR

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.